EN DE
Watch ECS Botanics Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ECS Botanics Holdings Ltd (ECS) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of ECS Botanics Holdings Ltd stock A$0.00, price A$0.00, that is 10.0% below the price, quality 30 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000052490

EB ECS Botanics Holdings Ltd logo Thin data Nov 14, 2026

ECS Botanics Holdings Ltd

ECS · AU

Expensive (fair value 10% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Mixed Growth (revenue 5y +75.9 %/yr in AUD) 
Mixed vs. peers (4/10) 
Profit last quarter 45% below a year ago. 
Changed on Nov 14: A$0.0045 → A$0.0036 
Fair value A$0.0036 · Overvalued 
Quality 30/100 
Falling price (downtrend) 
Loss-making · -9.1% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
⚠ Dilution
Watch ECS Botanics Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.0430 A$0.0030 Fair Value A$0.0036 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range A$0.0030 – A$0.0430 · the A$0.0040 price screens above the A$0.0036 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 5 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.

Follow ECS Botanics Holdings in your weekly email

Every Wednesday you see whether ECS Botanics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally. It is involved in the agriculture business. ECS Botanics Holdings Ltd is based in Murrabit, Australia.

Stock analysis

ECS Botanics Holdings Ltd (ECS) currently trades at A$0.0040, while our model-based Fair Value estimate is A$0.0036, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ECS Botanics Holdings Ltd reported revenue of A$21.0M in FY2026 versus A$5.3M in FY2022, a compound +41.1%/yr. Reported net income was −A$1.9M in FY2026.

Key figures

Market cap A$6.4M (≈ $4.3M) Micro · P/S ratio 0.38 · Net margin −9.1% · Return on equity −8.4% · Return on assets (EBIT) −13.5% (5-year average) · Operating margin −8.6% · Revenue (TTM) A$21.0M · Revenue growth (YoY) +0.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −10%, ECS screens cheaper than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) n/a A$0.0100 A$0.0100 50
All 1 models by family
Asset-Based
NCAV (Graham) n/a A$0.0100 A$0.0100 50

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.9%
Start year 2021 (pandemic). Over 10 years: +77.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+77.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−396.6% (2021) → −31.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ECS screens overvalued: fair value 10% below the price. Compare with Merck KGaA →

Compare ECS Botanics Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −10.0% · Above median
Profitability
Return on assets −6.0% · Bottom 25%
Net margin (12 months) −9.1% · Bottom 25%
Operating margin (12 months) −8.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.5% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.28× · Cheapest 25%
P/S (12 months) 0.31× · Cheapest 25%
EV/EBITDA 8.1× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 19
FUTURE (revenue growth)3 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs ECS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs ECS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs ECS
Haleon plc HLN $9.20 $8.47 −8% vs ECS
Merck KGaA MRK €149.70 €108.83 −27% vs ECS
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs ECS
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs ECS
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs ECS
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs ECS
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs ECS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ECS Botanics Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ECS Botanics Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ECS

Frequently asked questions

Is ECS Botanics Holdings Ltd (ECS) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of A$0.0036 versus a price of A$0.0040, about 10% lower (overvalued).
What is the fair value of ECS?
Our model-based fair value for ECS Botanics Holdings Ltd is A$0.0036 (as of Nov 14, 2026), built from audited fundamentals. The current price: A$0.0040.
What is the quality score of ECS?
ECS Botanics Holdings Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ECS Botanics Holdings Ltd (ECS)?
Our model-based price target is the fair value of A$0.0036 (as of Nov 14, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ECS Botanics Holdings Ltd stock forecast for 2026?
Our models put fair value at A$0.0036, about 10% lower versus a price of A$0.0040 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of ECS Botanics Holdings Ltd (ECS)?
ECS Botanics Holdings Ltd reported trailing-twelve-month revenue of about A$21.0M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of ECS Botanics Holdings Ltd (ECS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ECS Botanics Holdings Ltd it is A$0.0036 per share (as of Nov 14, 2026), against a price of A$0.0040. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is ECS Botanics Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ECS trades above its calculated fair value: price A$0.0040, fair value A$0.0036, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ECS?
No. The price is what the market pays today (A$0.0040); the fair value is what the company's own numbers justify (A$0.0036). For ECS Botanics Holdings Ltd the two are A$0.0004 per share apart. That gap is exactly why we show both numbers side by side.
How much is ECS Botanics Holdings Ltd worth?
The market values ECS Botanics Holdings Ltd at about A$6.4M (market capitalisation, as of Nov 14, 2026). Per share that is A$0.0040; our models calculate a fair value of A$0.0036 per share.
How solid is the balance sheet of ECS Botanics Holdings Ltd (ECS)?
Balance-sheet figures for ECS Botanics Holdings Ltd (as of Nov 14, 2026): return on equity −8.4%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ECS from its 52-week high?
ECS Botanics Holdings Ltd trades at A$0.0040, about 43% below its 52-week high of A$0.0070 and 33% above the low of A$0.0030 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0036 is for.
Which stocks are comparable to ECS Botanics Holdings Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ECS Botanics Holdings Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price A$0.0040, calculated fair value A$0.0036 (−10%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ECS calculated?
We run ECS Botanics Holdings Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0036 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. ECS Botanics Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ECS Botanics Holdings Ltd (ECS)?
The closing price on Nov 17, 2026 was A$0.0040. Our model-based fair value is A$0.0036, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ECS Botanics Holdings Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of ECS Botanics Holdings Ltd

How large is the market capitalisation of ECS Botanics Holdings Ltd (ECS)?
The market capitalisation of ECS Botanics Holdings Ltd is A$6.4M (≈ $4.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ECS Botanics Holdings Ltd (ECS)?
The price-to-sales ratio of ECS Botanics Holdings Ltd is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ECS Botanics Holdings Ltd (ECS)?
The net margin of ECS Botanics Holdings Ltd is −9.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ECS Botanics Holdings Ltd (ECS)?
The return on equity (ROE) of ECS Botanics Holdings Ltd is −8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ECS Botanics Holdings Ltd (ECS)?
On an EBIT basis the return on assets of ECS Botanics Holdings Ltd is −13.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ECS Botanics Holdings Ltd (ECS)?
The operating margin of ECS Botanics Holdings Ltd is −8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ECS Botanics Holdings Ltd (ECS)?
Revenue at ECS Botanics Holdings Ltd is growing 0.5% versus a year earlier (3y avg +11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ECS Botanics Holdings Ltd (ECS)?
Earnings per share at ECS Botanics Holdings Ltd are down 44.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ECS Botanics Holdings Ltd (ECS) generate?
The free cash flow of ECS Botanics Holdings Ltd is −A$508K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ECS Botanics Holdings Ltd (ECS) carry?
The net debt of ECS Botanics Holdings Ltd is A$5.2M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ECS Botanics Holdings Ltd in the live analysis

One click puts ECS Botanics Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.